Part, Chapter, Paragraph
1 II, 5. 1. 2| but these diagnostic and therapeutic tools are strictly bound
2 II, 5. 1. 2| rehabilitation, home visiting nurses, therapeutic patient education and patient
3 II, 5. 1. 3| 5.1.3. Therapeutic patient education~ ~The
4 II, 5. 1. 3| produced a document in 1998 on therapeutic patient education (Report
5 II, 5. 1. 3| of a WHO Working Group on Therapeutic Patient Education. Continuing
6 II, 5. 1. 3| compliance and adherence.~ ~Therapeutic patient education should
7 II, 5. 1. 3| related to health and illness. Therapeutic patient education has been
8 II, 5. 1. 3| of centres that practice therapeutic patient education, hoping
9 II, 5. 1. 3| behind this global need. Therapeutic patient education is a systemic,
10 II, 5. 1. 3| part of treatment and care.~Therapeutic patient education is about
11 II, 5. 1. 3| management of their condition. Therapeutic patient education is designed,
12 II, 5. 1. 3| patients and our society. Therapeutic patient education is essential
13 II, 5. 1. 3| excluded from its benefits. Therapeutic patient education is education
14 II, 5. 1. 3| purpose is to produce a therapeutic effect additional to that
15 II, 5. 2. 6| possible to reach the proper therapeutic target (plasma cholesterol
16 II, 5. 3. 8| bases of cancer offer new therapeutic possibilities every day
17 II, 5. 4. 2| and special diagnostic or therapeutic interventions can be obtained
18 II, 5. 4. 2| monitoring of the impact of therapeutic approaches and new medications
19 II, 5. 5. 3| major challenges of new therapeutic strategies and the development
20 II, 5. 5. 3| other hand, conventional therapeutic settings for detoxification
21 II, 5. 5. 3| as neglection of certain therapeutic options, non-compliance,
22 II, 5. 5. 3| should be based on three therapeutic columns – antipsychotic
23 II, 5. 5. 3| widely depending on the therapeutic setting, the kind of application
24 II, 5. 5. 3| One fifth does not have a therapeutic drug policy or an essential
25 II, 5. 5. 3| schizophrenia according to the therapeutic state of the art, this factor
26 II, 5. 5. 3| improving the diagnostic and therapeutic capabilities of each individual
27 II, 5. 5. 3| Consensus Paper~· Current therapeutic recommendations, from the
28 II, 5. 5. 3| C (2006): Review of the therapeutic management of Parkinson’
29 II, 5. 6. 3| management and use of different therapeutic strategies. However, most
30 II, 5. 6. 3| treatment with less effective therapeutic agents than those currently
31 II, 5. 6. 6| the knee. Diagnostic and Therapeutic Criteria Committee of the
32 II, 5. 7. 7| evaluating risk factors and therapeutic strategies. Nephrol Dial
33 II, 5. 15. 4| preventive, diagnostic and therapeutic interventions. This sector
34 II, 5. 15. 5| research and development of therapeutic solutions; the establishment
35 II, 8. 2. 1| 2005) Melbourne, Australia: Therapeutic Guidelines Limited.~Linehan,
36 II, 9 | the potential dangers of therapeutic drugs taken during early
37 II, 9. 1. 2| the potential dangers of therapeutic drugs taken during early
38 II, 9. 4. 5| approach in both preventive and therapeutic care of older people.~ ~
39 III, 10. 2. 2| possible to reach the proper therapeutic target (plasma cholesterol
40 III, 10. 2. 4| prognostic, diagnostic, or therapeutic purposes (Torhorst et al.,
41 III, 10. 4. 2| particular risk to humans, as therapeutic options to treat the disease
42 IV, 11. 3. 2| incentives to reward the therapeutic value of a drug and clinical
43 IV, 11. 3. 2| agents (figure 11.5).~ ~Therapeutic focus of products approved
44 IV, 11. 3. 2| 2008-2010~ ~Figure 11.6. Therapeutic focus of products approved
45 IV, 11. 3. 2| shows stability in the main therapeutic areas with the class of
46 IV, 11. 5. 4| No 26 on the exchange of therapeutic substances of human origin
47 IV, 12. 1 | ethical aspects in the case of therapeutic substances of human origin.
48 IV, 12. 10 | health forum~Low~--~--~Human therapeutic substances: quality, safety
49 IV, 13. 7 | medicinal products. The therapeutic use of tissues and cells
